160 related articles for article (PubMed ID: 34401716)
1. Health-Related Quality of Life in Focal Segmental Glomerular Sclerosis and Minimal Change Disease: A Qualitative Study of Children and Adults to Inform Patient-Reported Outcomes.
Carlozzi NE; Massengill SF; Trachtman H; Walsh L; Singhal N; LaVigne JM; Miner JA; Desmond HE; Lynam C; Gipson DS
Kidney Med; 2021; 3(4):484-497.e1. PubMed ID: 34401716
[TBL] [Abstract][Full Text] [Related]
2. Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.
Mathias SD; Vallow S; Gipson DS; Thorneloe KS; Sprecher D
Am J Kidney Dis; 2017 Oct; 70(4):532-540. PubMed ID: 28663063
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
[TBL] [Abstract][Full Text] [Related]
4. Development of a Conceptual Model for the Patient Experience of Focal Segmental Glomerulosclerosis (FSGS): A Qualitative Targeted Literature Review.
Aldhouse NVJ; Kitchen H; Al-Zubeidi T; Thursfield M; Winnette R; See Tai S; Zhu L; Garnier N; Baker CL
Adv Ther; 2023 Dec; 40(12):5155-5167. PubMed ID: 37819555
[TBL] [Abstract][Full Text] [Related]
5. Minimal change disease and idiopathic focal segmental glomerulosclerosis in adults. A quantitative study.
Danilewicz M; Wagrowska-Danilewicz M
Pol J Pathol; 1996; 47(4):209-14. PubMed ID: 9097714
[TBL] [Abstract][Full Text] [Related]
6. Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.
Pérez V; López D; Boixadera E; Ibernón M; Espinal A; Bonet J; Romero R
BMC Nephrol; 2017 Feb; 18(1):49. PubMed ID: 28158993
[TBL] [Abstract][Full Text] [Related]
7. Urinary peptide profiling to differentiate between minimal change disease and focal segmental glomerulosclerosis.
Pérez V; Ibernón M; López D; Pastor MC; Navarro M; Navarro-Muñoz M; Bonet J; Romero R
PLoS One; 2014; 9(1):e87731. PubMed ID: 24498182
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin G/albumin staining in tubular protein reabsorption droplets in minimal change disease and focal segmental glomerulosclerosis.
Bu L; Mirocha J; Haas M
Nephrol Dial Transplant; 2021 May; 36(6):1016-1022. PubMed ID: 32191308
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Study on Complement Activation Distinguishes Focal Segmental Glomerulosclerosis from Minimal Change Disease.
Cambier A; Patey N; Royal V; Gougeon F; Genest DS; Brachemi S; Bollée G; Merlen C; Bonnefoy A; Lapeyraque AL; Troyanov S
Kidney Int Rep; 2024 Mar; 9(3):661-670. PubMed ID: 38481495
[TBL] [Abstract][Full Text] [Related]
10. The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network.
Troost JP; Waldo A; Carlozzi NE; Murphy S; Modersitzki F; Trachtman H; Nachman PH; Reidy KJ; Selewski DT; Herreshoff EG; Srivastava T; Gibson KL; Derebail VK; Lin JJ; Hingorani S; Fornoni A; Fervenza FC; Sambandam K; Athavale AM; Kopp JB; Reich HN; Adler SG; Greenbaum LA; Dell KM; Appel G; Wang CS; Sedor J; Kaskel FJ; Lafayette RA; Atkinson MA; Lieske JC; Sethna CB; Kretzler M; Hladunewich MA; Lemley KV; Brown E; Meyers KE; Gadegbeku CA; Holzman LB; Jefferson JA; Tuttle KR; Singer P; Hogan MC; Cattran DC; Barisoni L; Gipson DS;
Clin Kidney J; 2020 Aug; 13(4):597-606. PubMed ID: 32905199
[TBL] [Abstract][Full Text] [Related]
11. Synaptopodin immunoexpression in steroid-responsive and steroid-resistant minimal change disease and focal segmental glomerulosclerosis.
Wagrowska-Danilewicz M; Danilewicz M
Nefrologia; 2007; 27(6):710-5. PubMed ID: 18336100
[TBL] [Abstract][Full Text] [Related]
12. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults.
Tune BM; Mendoza SA
J Am Soc Nephrol; 1997 May; 8(5):824-32. PubMed ID: 9176855
[TBL] [Abstract][Full Text] [Related]
13. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.
Mariani LH; Bomback AS; Canetta PA; Flessner MF; Helmuth M; Hladunewich MA; Hogan JJ; Kiryluk K; Nachman PH; Nast CC; Rheault MN; Rizk DV; Trachtman H; Wenderfer SE; Bowers C; Hill-Callahan P; Marasa M; Poulton CJ; Revell A; Vento S; Barisoni L; Cattran D; D'Agati V; Jennette JC; Klein JB; Laurin LP; Twombley K; Falk RJ; Gharavi AG; Gillespie BW; Gipson DS; Greenbaum LA; Holzman LB; Kretzler M; Robinson B; Smoyer WE; Guay-Woodford LM;
Am J Kidney Dis; 2019 Feb; 73(2):218-229. PubMed ID: 30420158
[TBL] [Abstract][Full Text] [Related]
14. Morphological Features of Minimal Change Disease and Focal Segmental Glomerulosclerosis Using Repeat Biopsy and Parietal Epithelial Cell Marker.
Suzuki T; Kohatsu K; Han W; Watanabe S; Yahagi K; Nakata M; Ueno T; Ichikawa D; Imai N; Shirai S; Koike J; Shibagaki Y
Kidney Dis (Basel); 2020 Mar; 6(2):119-124. PubMed ID: 32309294
[TBL] [Abstract][Full Text] [Related]
15. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.
Ramezani A; Devaney JM; Cohen S; Wing MR; Scott R; Knoblach S; Singhal R; Howard L; Kopp JB; Raj DS
Eur J Clin Invest; 2015 Apr; 45(4):394-404. PubMed ID: 25682967
[TBL] [Abstract][Full Text] [Related]
16. Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies.
Pereira LHM; da Silva CA; Monteiro MLGDR; Araújo LS; Rocha LP; Reis MBDR; Ramalho FS; Corrêa RRM; Silva MV; Reis MA; Machado JR
PLoS One; 2019; 14(6):e0217569. PubMed ID: 31188898
[TBL] [Abstract][Full Text] [Related]
17. Childhood minimal change disease and focal segmental glomerulosclerosis: a continuous spectrum of disease? Pathologic study of 33 cases with long-term follow-up.
Lichtig C; Ben-Izhak O; On A; Levy J; Allon U
Am J Nephrol; 1991; 11(4):325-31. PubMed ID: 1799192
[TBL] [Abstract][Full Text] [Related]
18. Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease.
Chebotareva NV; Vinogradov A; Brzhozovskiy AG; Kashirina DN; Indeykina MI; Bugrova AE; Lebedeva M; Moiseev S; Nikolaev EN; Kononikhin AS
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293475
[TBL] [Abstract][Full Text] [Related]
19. Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental Glomerulosclerosis.
Gipson DS; Troost JP; Spino C; Attalla S; Tarnoff J; Massengill S; Lafayette R; Vega-Warner V; Adler S; Gipson P; Elliott M; Kaskel F; Fermin D; Moxey-Mims M; Fine RN; Brown EJ; Reidy K; Tuttle K; Gibson K; Lemley KV; Greenbaum LA; Atkinson MA; Hingorani S; Srivastava T; Sethna CB; Meyers K; Tran C; Dell KM; Wang CS; Yee JL; Sampson MG; Gbadegesin R; Lin JJ; Brady T; Rheault M; Trachtman H
JAMA Netw Open; 2022 Aug; 5(8):e2228701. PubMed ID: 36006643
[TBL] [Abstract][Full Text] [Related]
20. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.
Stokes MB; Markowitz GS; Lin J; Valeri AM; D'Agati VD
Kidney Int; 2004 May; 65(5):1690-702. PubMed ID: 15086908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
